Vioquest Pharmaceuticals Inc. (VOQP)
OTC PINK OTC PINK Primary Summary
Vioquest Pharmaceuticals Inc. (VOQP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vioquest Pharmaceuticals Inc. ever had a stock split?
Vioquest Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark D. Dacko CEO | OTC PINK Exchange | 927625202 CUSIP |
| US Country | 3 Employees | - Last Dividend | 30 Apr 2008 Last Split | 11 May 1987 IPO Date |
Overview
VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of clinical-stage drug therapies. These therapies primarily focus on the treatment of oncology and infectious diseases. Founded in 2000, the company has established its headquarters in Basking Ridge, New Jersey. Through its extensive research and development efforts, VioQuest strives to bring innovative treatments to market, aiming to address complex medical conditions and improve patient outcomes.
Products and Services
Xyfid
Under development for the treatment and prevention of hand-foot syndrome, Xyfid represents VioQuest's lead product. Hand-foot syndrome is a common side effect of certain chemotherapy drugs, characterized by redness, swelling, and pain on the palms of the hands and soles of the feet. Xyfid aims to alleviate these symptoms, thereby improving the quality of life for patients undergoing chemotherapy.
VQD-002
A nucleoside analog currently in Phase I clinical trials, VQD-002 is aimed at treating cancer. The development of this drug highlights the company's commitment to targeting cancer treatment through innovative pharmacological approaches, potentially offering new hope for patients battling various forms of cancer.
Lenocta
In Phase IIa clinical trials, Lenocta is a small molecule inhibitor targeting various protein tyrosine phosphatases. These enzymes are implicated in several types of cancer, including melanoma, renal cell carcinoma, and other solid tumors. By inhibiting these enzymes, Lenocta may provide a novel mechanism for cancer therapy, addressing tumors that are resistant to current treatments.
Chiral Products, Technology, and Custom Synthesis Development Services
In addition to its focus on drug development, VioQuest Pharmaceuticals offers a range of chiral products, technology solutions, and custom synthesis development services. These services cater to pharmaceutical and fine chemical companies at various stages of a product's lifecycle. By leveraging its expertise in chiral chemistry, VioQuest provides valuable support for the development and manufacture of complex pharmaceutical compounds.
